2023-11-13 09:28:17
Shares of Novo Nordisk rose 3.3% on Monday as the market reacted to data presented by the drugmaker over the weekend that showed the heart-protecting benefits of its popular obesity drug , Wegovy, are not only due to weight loss.
Data presented Saturday at a major U.S. medical meeting boosted investors’ and analysts’ confidence in Wegovy’s cardiac benefits, following Novo released preliminary data from a large study in August, which sent shares up 17% on the day, hitting record highs.
1699868226
#Novo #Nordisk #shares #rise #Wegovy #shows #heart #benefits #weight #loss #November #a.m
